Table 2 Differences in variables included in propensity score in the matched cohort
No VAP (n = 78) | VAP (n = 78) | Difference between means (95% CI) | p-value | |
|---|---|---|---|---|
Gender (male), n (%) | 56 (71.8) | 60 (76.9) | 5.1 (− 8.5 to 18.8) | 0.463 |
Admission to an open ICU unit, n (%) | 46 (59) | 47 (60.3) | 1.3 (− 14.1 to 16.7) | 0.87 |
APACHE II, median (IQR) | 10 (7–13) | 11.5 (9–14) | − 0.5 (− 2 to 1) | 0.758 |
SOFA, median (IQR) | 4 (3–5) | 4 (3–5) | − 0.1 (− 0.7 to 0.5) | 0.759 |
Corticosteroids, n (%) | 28 (35.9%) | 32 (41%) | 5.1 (− 10.1 to 20.4) | 0.51 |
Tocilizumab, n (%) | 55 (70.5%) | 53 (68%) | − 2.6 (− 17 to 11.9) | 0.729 |
Length of MV (days), median (IQR) | 12 (8–20) | 24 (17–33) | − 11.2 (− 17.1 to − 5.3) | < 0.001 |
Length of ICU stay, median (IQR) | 15 (9–23) | 25 (20–34) | − 11.6 (− 17.9 to − 5.3) | < 0.001 |
ICU Mortality, n (%) | 11 (14.1%) | 25 (32.1%) | − 17.9 (− 30.9 to − 5.0) | < 0.01 |